KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Finished Goods (2016 - 2018)

Emergent BioSolutions' Finished Goods history spans 8 years, with the latest figure at $50.8 million for Q4 2018.

  • For Q4 2018, Finished Goods rose 68.77% year-over-year to $50.8 million; the TTM value through Dec 2018 reached $50.8 million, up 68.77%, while the annual FY2018 figure was $50.8 million, 68.77% up from the prior year.
  • Finished Goods reached $50.8 million in Q4 2018 per EBS's latest filing, up from $27.1 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $50.8 million in Q4 2018 to a low of $6.9 million in Q4 2015.
  • Average Finished Goods over 5 years is $23.0 million, with a median of $23.9 million recorded in 2015.
  • Peak YoY movement for Finished Goods: surged 669.76% in 2014, then crashed 58.88% in 2017.
  • A 5-year view of Finished Goods shows it stood at $14.8 million in 2014, then crashed by 53.43% to $6.9 million in 2015, then surged by 240.34% to $23.5 million in 2016, then grew by 28.12% to $30.1 million in 2017, then skyrocketed by 68.77% to $50.8 million in 2018.
  • Per Business Quant, the three most recent readings for EBS's Finished Goods are $50.8 million (Q4 2018), $27.1 million (Q3 2018), and $25.4 million (Q2 2018).